🆕Our October issue is live! 📊Articles: #ovariancancer, #breastcancer, #multiplemyeloma, #prostatecancer, #lungcancer 📉Trials: KEYLYNK-001, CHN HYPOPMRT, SYMPRO-Lung trial, OPTIMUM/MUKnine, STAMINA 🎨Cover: Cancer & the microbiome Read here: thelancet.com/issue/S1470-...

Just launched: Accelerating equitable cancer genomics and precision oncology in health care and research: a @thelancetoncol.bsky.social Commission With a new framework, implementation could be more equitable, effective, and sustainable Read more: thelancet.com/commissions-...

Cancer genetic testing and precision oncology are advancing rapidly—but access is not. A new @thelancetoncol.bsky.social Commission sets out how health systems can scale these innovations equitably and sustainably: spkl.io/633287TYKi #WCC2026

🚨Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial 📑Read here: thelancet.com/journals/lan... 📺Watch here: youtu.be/3OH_3uAj-xE?...

Radiotherapy after Mastectomy: 5-Year Results

YouTube video by The Lancet

youtu.be

🔴Online now: Global health expenditures on cancer control: a cross-sectional analysis "By making cancer expenditures visible and comparable, this work helps create an evidence base to inform priority setting and allocation decisions for cancer control." thelancet.com/journals/lan...

Attending #WorldCancerCongress #WCC2026 in Hong Kong? Join us for the launch of the new @thelancetoncol.bsky.social Commission on Accelerating equitable cancer genomics and precision oncology Friday Sept 25, 2026 at 11:10 AM (Asia/Hong Kong)

🔴Online now: Patient-reported symptom monitoring in patients with lung cancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cluster-randomised clinical trial thelancet.com/journals/lan...

📽️Watch now: Unpicking the UK's cancer response after Brexit: what broke, what was patched up, and what still matters Read the full Essay in @thelancetoncol.bsky.social youtu.be/HIYHaqbK9UY?...

The UK's Cancer Care after Brexit

YouTube video by The Lancet

youtu.be

🎧Listen & subscribe to our Sept podcast: Prof Sherene Loi and the International Immuno-Oncology Biomarker Working Group on TILs in breast cancer Spotify: open.spotify.com/show/3JOj0Cl... Apple: podcasts.apple.com/us/podcast/t... Sept issue: www.thelancet.com/issue/S1470-...

Looking forward to this year's #WorldCancerCongress #WCC2026 where our Editor-in-Chief will be chairing three sessions including two on Commissions from @thelancetoncol.bsky.social and a Rapid Fire session on some of the latest research. See you in Hong Kong!

🆕Our Sept issue is now live! 📊Articles: #hepatocellularcarcinoma #NSCLC #rectalcancer #breastcancer #prostatecancer 📉Featuring trials: EMERALD-3, HARMONi, ALINA, STAR-TREC, & GETUG AFU 18 🎨Cover: breast cancer, TILs, and AI 🖱️Read here: www.thelancet.com/issue/S1470-...

🔴Online now: ChemoRT vs short-course RT for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of a randomised, phase 2/3 trial 📉Article: thelancet.com/journals/lan... & ✏️ Comment: thelancet.com/journals/lan...

Triple-negative breast cancer is the most aggressive form of the disease, & it often spreads to the brain. Treatment options remain limited. A Review in @thelancetoncol.bsky.social draws together the latest evidence to provide a roadmap for unmet clinical needs. Find out more: tinyurl.com/3s3nez22

Novel strategies to overcome the blood–brain barrier in triple-negative breast cancer brain metastases

Triple-negative breast cancer—the most aggressive breast cancer subtype—has a high propensity for brain metastases, with limited treatments and poor prognosis. The blood–brain barrier, long viewed as ...

tinyurl.com

📢Register now for our free #Webinar "Transforming the Landscape of #GynaecologicalCancer: Advances in Prevention, Precision Surgery, and Innovative Systemic Therapies" on Sept 3: irc.ad/the-lancet-g... Read the linked Series here: thelancet.com/series-do/gy... @chrustrasbourg.bsky.social

🆕Our Aug issue is live! 📊Articles: #bladdercancer #Breastcancer #urothelialcarcinoma #NSCLC 📉Trials: HORIZON-Breast01, SERENA-6, SUPREMO, JCOG1403, BOND-003, PICC-2, PERISCOPE II 🎨Cover: Advancing oncology education in LMIC African settings 🖱️https://www.thelancet.com/issue/S1470-2045(26)X2007-1

🚨Online now: Efficacy and safety of dabrafenib plus trametinib in adults with differentiated #thyroidcancer: a randomised, double-blind, placebo-controlled, phase 3 trial 📊Read here: thelancet.com/journals/lan... 📝Linked comment: thelancet.com/journals/lan...

🚨Our July podcast! Hans Merks on European guidelines for imaging of primary paediatric and adult osteosarcoma and Ewing sarcoma 🎧Listen & subscribe: Spotify open.spotify.com/show/3JOj0Cl... Apple podcasts.apple.com/us/podcast/t... 📕Read here: www.thelancet.com/pdfs/journal...

Ready to share your #ClinicalOncology research with millions globally? Explore our author resources for a seamless submission process, and start your publication journey with us today: hubs.li/Q04mkDC40

The Lancet Oncology@thelancetoncol.bsky.social · 3mo ago

Behind every paper is a community. To every author who trusted us with their research and every peer reviewer who gave their time and expertise—thank you! Together, we are advancing the best science for better lives. Learn about our peer review process: hubs.li/Q04mCzF70

Behind every paper is a community. To every author who trusted us with their research and every peer reviewer who gave their time and expertise—thank you! Together, we are advancing the best science for better lives. Learn about our peer review process: hubs.li/Q04mCzF70

The Lancet Oncology@thelancetoncol.bsky.social · 3mo ago

We are an internationally trusted journal for clinical and global #oncology, with a:   Journal Impact Factor of 33·7  Scopus CiteScore of 42·0  Explore our high impact and global reach: hubs.li/Q04k_cRQ0 #ClinicalOncology #MedicalResearch #ClinicalTrials

We are an internationally trusted journal for clinical and global #oncology, with a:   Journal Impact Factor of 33·7  Scopus CiteScore of 42·0  Explore our high impact and global reach: hubs.li/Q04k_cRQ0 #ClinicalOncology #MedicalResearch #ClinicalTrials

✏️Our July Editorial: Historic moments "Attending large scientific conferences can be an endurance test....but occasionally, it becomes apparent that the conference in question is different, that something historic has happened." Read here: thelancet.com/journals/lan...

The Lancet Oncology@thelancetoncol.bsky.social · 3mo ago

🆕Our July issue is live! 📊Articles: #NSCLC #Breastcancer #prostatecancer #glioblastoma 📉Trials: AENEAS2, SUBITO, EORTC 22922/10925, ARTO, PRIMARY2, CAIRO6, & INTRAGO-II 🎨Cover: Meta-analysis on AEs of CD3 T cell-engaging bispecific abs Read here: thelancet.com/issue/S1470-...

📢 New @thelancetoncol.bsky.social publication insights from EORTC trial 22922/10925 focusing on an unplanned subset analysis of patients with node-negative (pN0) breast cancer with centrally or medially located tumours. 🎥 Watch video & learn more: www.eortc.org/blog/2026/05... #EORTCbreast

🆕Our July issue is live! 📊Articles: #NSCLC #Breastcancer #prostatecancer #glioblastoma 📉Trials: AENEAS2, SUBITO, EORTC 22922/10925, ARTO, PRIMARY2, CAIRO6, & INTRAGO-II 🎨Cover: Meta-analysis on AEs of CD3 T cell-engaging bispecific abs Read here: thelancet.com/issue/S1470-...

🆕Our June issue is live! 📊Articles: #prostatecancer, #breastcancer, #kidneycancer, #RCC, #glioma 📉Including trials: CAN-2409, FAST-Forward, OCLURANDOM, FASTRACK, & UNITED ✏️Perspective: Equity in Germany's National Lung Cancer Screening Read here: thelancet.com/issue/S1470-...

🚨 Attend the #ASCO26 session today: A Workforce Crisis—A Lancet Oncology Commission May 31, 2026, 4:30 PM-5:45 PM CDT at #ASCO 📕Booklet available at outside session and online 🖱️http://thelancet.com/commissions-do/cancer-workforce 📽️ youtu.be/VYr2Bjmxyhg

Cancer workforce—a global crisis

YouTube video by The Lancet

youtu.be

Heading to #ASCO26? Reach out to Dr David Collingridge, Editor-in-Chief at @thelancetoncol.bsky.social, attending #ASCO26 🗓️ Attend the Global Oncology: A Workforce Crisis—A Lancet Oncology Commission session May 31, 2026, 4:30 PM-5:45 PM CDT #cancerworkforce meetings.asco.org/meetings/202...

Heading to #ESTRO26? Attend our Top Clinical Trials session, May 17 Reach out to Cheryl Lai, Deputy Editor at @thelancetoncol.bsky.social, attending #ESTRO and say hello!

🎉Proud to share our first online article by @nathaliealbert.bsky.social & colleagues that was presented at #NMN2026 @nmnsymposium.bsky.social www.thelancet.com/action/showF...

Imaging-based classification of blood–brain barrier disruption in glioblastoma for patient selection in clinical trials: the NMN-BBB score

The blood–brain barrier (BBB) limits the activity of novel treatments, such as pharmacotherapies and targeted radionuclide therapies in glioblastoma. Selection of patients with extensive tumoural BBB ...

thelancet.com

@thelancetoncol.bsky.social news desk: www.thelancet.com/journals/lan...

US Senate Bill aims to boost cancer trial enrolment and equity

One in five cancer clinical trials in the USA fail due to insufficient patient enrolment, according to a report from the American Cancer Society Cancer Action Network. Recruitment challenges are pushi...

thelancet.com

🎧Our May podcast: Cheryl Lai is joined by Fred Saad (Montreal) to discuss pain and HRQOL outcomes from the ARANOTE trial in metastatic hormone-sensitive prostate cancer 📊Article: www.thelancet.com/journals/lan... Spotify: open.spotify.com/episode/1EGt... Apple: podcasts.apple.com/us/podcast/t...

The Lancet Oncology@thelancetoncol.bsky.social · 5mo ago

🆕Our May issue is live! 📊Articles: #breastcancer, #prostatecancer, and #softtissuesarcoma 📑Reviews: Clinical trial endpoints for metastases-directed therapy in oligometastatic cancer from the EORTC–ESTRO OligoCare consortium Read here: thelancet.com/issue/S1470-...